The Alliance for Regenerative Medicine and the Bioindustry Association of the UK have released a report (Report) concerning development and growth of the cell and gene therapy field in the United Kingdom. The Report notes “four key takeaways”:
The Report states that 24% of ATMP companies in Europe are headquartered in the United Kingdom, additionally there was over a billion US dollars in funding. The funding in 2019 is on track to meet or exceed 2018’s funding. There are detailed stats on funding by type in the Report. Moreover, since 2012, there has been a substantial uptick in ATMP activity—from 22 companies to over 70 companies, some of which is attributed to significant government support and organization. The Report also contains data regarding current and past clinical trials and case studies concerning relevant companies and their technology.
The Report concludes with the following recommendations:
The development of a skilled workforce (and attraction of one) and the related issue of international collaboration is important, but not expressly tied together in the recommendations. The full Report is available, here.